Abstract
In their recently published article Erbs et al. aimed to evaluate the pleiotropic effects of rosuvastatin on vascular and tissue regeneration, its impact on endothelial function and hemodynamics in 42 patients with chronic heart failure (CHF) [ [1] Erbs S. Beck E.B. Linke A. Adams V. Gielen S. Kränkel N. et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling — results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol. 2010 Mar 15; (Electronic publication ahead of print) PubMed Google Scholar ]. They found that rosuvastatin activates circulating progenitor cells (CPCs) that contribute to neovascularisation and to the enhancement of endothelial function in CHF. Also they demonstrated that rosuvastatin improved LV performance by partly correction of vascular abnormalities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
